Patrys Limited (ASX: PAB), a clinical-stage reformulation and antibody development company, has completed critical operational milestones to advance its lead asset RLS-2202 toward Phase 1A clinical development. The company has appointed CMAX as the Phase 1A clinical trial site and Alithia Life Sciences as the Contract Research Organisation, establishing the infrastructure required for early-stage human testing. With a successful A$3.1 million capital raise completed during the June quarter, Patrys targets first participant dosing in Q3 2026, subject to regulatory approvals.
Key Points
- Patrys Limited (ASX: PAB) is a clinical-stage company developing RLS-2202, an injectable formulation of quetiapine for treating delirium in acute care settings
- CMAX appointed as Phase 1A clinical trial site; Alithia Life Sciences appointed as Contract Research Organisation to oversee trial operations and regulatory management
- Phase 1A Human Research Ethics Committee application submitted; drug product for cohort 1 manufactured and awaiting release; first participant dosing targeted for Q3 2026 subject to regulatory approvals
- A$3.1 million placement completed at A$0.024 per share, with placement participants receiving one free unlisted option for every four shares subscribed at A$0.048 exercisable by 30 November 2030
- Company closed June quarter with A$3.36 million in cash; net operating cash outflows of A$789,000 reflected investment in RLS-2202 advancement and intellectual property protection
- Post-quarter: Patrys entered binding agreement regarding deoxymab intellectual property portfolio, retaining 50% of future commercialisation revenue while reducing capital requirements
RLS-2202 Regulatory Pathway and Clinical Development Strategy
RLS-2202 represents Patrys' lead clinical asset, positioned as a proprietary injectable formulation of quetiapine designed to treat delirium in acute care settings. The company has selected the FDA 505(b)(2) regulatory pathway for RLS-2202, a strategy that enables Patrys to leverage the extensive existing clinical and safety data already established for quetiapine while generating new data specific to its proprietary injectable formulation. This regulatory approach is intended to streamline the development and approval process by building on the known safety profile of the active pharmaceutical ingredient while demonstrating the benefits of the company's novel formulation.
The Phase 1A bridging study in healthy volunteers represents a critical early development milestone for the program. This study is specifically designed to assess safety, tolerability and pharmacokinetics of the RLS-2202 formulation. The bridging study approach allows Patrys to establish key data in healthy subjects before advancing to patient populations, a standard approach in early-stage clinical development. By generating this formulation-specific safety and pharmacokinetic data, the company aims to support the subsequent progression of RLS-2202 toward later-stage clinical evaluation in delirium patients in acute care settings.
CMAX and Alithia Life Sciences Appointment: Establishing Clinical Trial Infrastructure
During the June quarter, Patrys completed a competitive evaluation process and appointed CMAX as the Phase 1A clinical trial site and Alithia Life Sciences as the Contract Research Organisation. CMAX will be responsible for participant dosing and monitoring, leveraging its specialist Phase 1 infrastructure, experienced investigators and established participant recruitment capabilities. The selection of CMAX reflects the importance of access to both the physical infrastructure and human expertise required to safely conduct early-stage human studies with adequate participant recruitment and follow-up.
Alithia Life Sciences will oversee the broader operational, regulatory and clinical management of the trial, with responsibilities spanning project management, regulatory coordination, data management, pharmacovigilance, vendor oversight, biostatistics and reporting. These appointments establish the complete operational framework required to execute the Phase 1A clinical trial. The company noted that these selections followed a competitive evaluation process and reflect both organisations' extensive experience in early-stage clinical development, Phase 1 execution and safety oversight. The division of responsibilities between trial site and CRO allows for specialised expertise and oversight across the multiple functions required for successful trial execution.
Phase 1A Study Planning Progress and HREC Submission
Phase 1A study planning advanced substantially during the June quarter, with Patrys completing protocol finalisation and submitting its Human Research Ethics Committee (HREC) application. The protocol finalisation represents a critical step in the regulatory pathway, as the clinical protocol outlines the detailed methodology, safety procedures, participant inclusion and exclusion criteria, and data collection procedures that will govern the trial. This comprehensive planning phase ensures that all aspects of trial conduct are fully specified and aligned with regulatory requirements before trial initiation.
Patrys reported that drug product for cohort 1 of the clinical trial has been manufactured and is currently awaiting release, indicating that manufacturing activities are proceeding in parallel with regulatory submissions. The company continued trial initiation activities at CMAX during the quarter, working through the practical and operational aspects of preparing the site for participant enrollment. Subject to HREC approval and other applicable approvals—including Therapeutic Goods Administration Complaint Therapeutic Note (TGA CTN) notification, site governance approval and trial registration with the Australian and New Zealand Clinical Trials Registry (ANZCTR)—first participant dosing remains targeted for Q3 2026. This timeline assumes successful progression through the multiple approval pathways required before human dosing can commence.
Capital Raise of A$3.1 Million Supporting Clinical Progression
Patrys completed a successfully supported placement during the June quarter, raising approximately A$3.1 million (before costs) through the issue of approximately 131 million fully paid ordinary shares at A$0.024 per share. Following shareholder approval at a General Meeting held on 8 June 2026, placement participants became entitled to receive one free attaching unlisted option for every four shares subscribed, with these options exercisable at A$0.048 on or before 30 November 2030. The inclusion of options as part of the placement structure is designed to align shareholder interests with the company's value creation objectives as it progresses RLS-2202 toward clinical and regulatory milestones.
Directors of the company participated in the placement on identical terms to other investors, with directors investing an additional A$210,000, demonstrating management confidence in the company's strategic direction. The capital raised was explicitly intended to support near-term clinical and regulatory milestones, including execution of the Phase 1A clinical trial, associated manufacturing and regulatory activities, continued advancement of the company's intellectual property portfolio and general working capital. The successful completion of the placement reflected investor appetite for the company's clinical development program and provided the balance sheet strength required to fund the planned progression of RLS-2202 through early-stage clinical development.
Cash Position and Operating Expenditure During June Quarter
Patrys closed the June quarter with A$3.36 million in cash, reflecting the company's position following the capital raise and ongoing operational expenditure. Net operating cash outflows during the quarter totalled A$789,000, with this expenditure primarily reflecting continued investment in advancing RLS-2202 across multiple workstreams including manufacturing, regulatory and clinical planning activities. The company also maintained ongoing investment in intellectual property protection across both the RLS-2202 and deoxymab programs, representing the company's commitment to securing and maintaining proprietary protection for its technology platforms.
Payments to related parties and their associates during the quarter, detailed in Section 6 of the accompanying Appendix 4C, totalled A$74,610. These payments relate to Non-Executive Director fees and represent ordinary course compensation for board-level governance functions. The operating cash burn rate during the quarter reflects the company's stage of development, with investments focused on the advancement activities required to progress toward the Phase 1A clinical trial initiation. The company's cash position and burn rate are important metrics for investors monitoring the runway available to fund planned clinical development activities.
Deoxymab Platform and Post-Quarter Development Agreement
Beyond its lead RLS-2202 program, Patrys continues to develop a differentiated deoxymab platform targeting immune-mediated inflammatory diseases. The deoxymab platform represents a distinct therapeutic approach within the company's overall development portfolio. During the June quarter, the company continued supporting ongoing clinical research of the deoxymab program through external collaborations, including vasculitis pre-clinical research involving the compounds DX1 and DX3. This collaborative approach allows Patrys to maintain involvement with the program while managing capital requirements and leveraging external research expertise.
Subsequent to the end of the June quarter, Patrys entered into a binding agreement establishing a new pathway for continued development and commercialisation of its deoxymab intellectual property portfolio. Under this agreement, Patrys retains a 50% share of future commercialisation revenue attributable to the deoxymab intellectual property while materially reducing the future capital requirements associated with advancing the program. This structure allows the company to maintain economic interest in successful commercialisation outcomes while transferring development and commercialisation responsibilities and associated capital obligations. The company indicated that it will continue supporting ongoing clinical research of the deoxymab program through external collaborations. Further details regarding this post-quarter agreement were contained in a separate company announcement dated 13 July 2026.
Clinical Development Stage and Company Positioning
Patrys is positioned as a clinical-stage company, with RLS-2202 representing its lead asset advancing toward human testing. The clinical-stage classification indicates that the company has completed preclinical development activities and is now progressing toward Phase 1 clinical evaluation in healthy human volunteers. This stage represents a material progression in the typical drug development pathway, as human clinical data generation begins to inform the regulatory and commercial viability of the candidate therapy. The transition from preclinical to clinical development is typically associated with increased development costs and timelines, reflecting the comprehensive safety, efficacy and manufacturing data required by regulatory authorities before any new therapy can be approved for commercial distribution.
The company's dual platform approach—focusing on RLS-2202 while maintaining involvement with the deoxymab platform through its post-quarter agreement—provides diversification within the company's development portfolio. This approach allows Patrys to advance its lead clinical asset while maintaining upside exposure to the deoxymab program's commercial potential. The company's positioning as a clinical-stage developer reflects its current stage of maturity, with the next key phases involving progression through Phase 1A studies, potential Phase 2 development, and ultimately regulatory submission based on the data generated.
Investor Considerations and Development Timeline
Investors monitoring Patrys should note that the company's key near-term milestone is first participant dosing in RLS-2202's Phase 1A study, targeted for Q3 2026 subject to regulatory approvals. The achievement of this milestone would represent material progression in the clinical development pathway and would begin generating human safety and pharmacokinetic data for the RLS-2202 formulation. However, this timeline remains subject to receipt of HREC approval, TGA CTN notification clearance, site governance approval and ANZCTR trial registration. Any delays in obtaining these regulatory clearances could extend the timeline for first participant dosing.
The successful capital raise during the June quarter has positioned the company to fund operations through the planned Phase 1A study progression, with the A$3.36 million cash balance and A$789,000 quarterly burn rate suggesting approximate runway for several quarters of operations at current spending levels, assuming no additional capital raising or changes in expenditure. The post-quarter agreement regarding the deoxymab platform also reduces future capital requirements by transferring development responsibilities while maintaining revenue upside, potentially extending the company's operational runway. Investors should monitor quarterly cash position updates and any announcements regarding Phase 1A study progression, regulatory approvals, and outcomes as key indicators of the company's development trajectory.
Regulatory and Clinical Trial Risk Factors
Patrys' development pathway involves multiple regulatory approval steps that must be successfully completed before first participant dosing can commence in the Phase 1A study. The company must obtain approval from the Human Research Ethics Committee, notification clearance from the Therapeutic Goods Administration, site governance approvals and trial registration with ANZCTR. Any of these regulatory steps could encounter delays or require modifications to the clinical protocol, potentially extending the timeline to first participant dosing beyond Q3 2026. Changes to regulatory requirements, ethical review procedures or TGA policy could also impact the approval timeline or require modifications to the planned study design.
Beyond regulatory approvals, clinical development carries inherent scientific risks. The Phase 1A study is designed to assess safety, tolerability and pharmacokinetics of RLS-2202; however, unexpected safety signals, tolerability issues or pharmacokinetic findings could emerge during human testing that were not apparent during preclinical evaluation. Such findings could require modifications to dosing strategies, further preclinical investigation or in extreme cases could raise questions about the overall viability of the formulation approach. Additionally, recruitment challenges or participant retention issues could impact the timeline and completeness of the Phase 1A study data generation. Investors should consider these clinical and regulatory risks when evaluating the company's development program.




Please wait processing your request...